MPGES-1 is considered as a promising therapeutic target of the next generation anti-inflammatory drugs in the research of inflammatory diseases. The IC 50 value of mPGES-1-IN-1 is 0.03 μ M。
PARP-1-IN-1 is a high selective and orally active PARP-1 inhibitor (IC50=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model[1].